@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP484365.RA4_VSli3kAx1b1cPALmw84JL1OiJHzfJThMyeYiS6Q8g130_head { this: np:hasAssertion dgn-np:NP484365.RA4_VSli3kAx1b1cPALmw84JL1OiJHzfJThMyeYiS6Q8g130_assertion; np:hasProvenance dgn-np:NP484365.RA4_VSli3kAx1b1cPALmw84JL1OiJHzfJThMyeYiS6Q8g130_provenance; np:hasPublicationInfo dgn-np:NP484365.RA4_VSli3kAx1b1cPALmw84JL1OiJHzfJThMyeYiS6Q8g130_publicationInfo; a np:Nanopublication . dgn-np:NP484365.RA4_VSli3kAx1b1cPALmw84JL1OiJHzfJThMyeYiS6Q8g130_assertion a np:Assertion . dgn-np:NP484365.RA4_VSli3kAx1b1cPALmw84JL1OiJHzfJThMyeYiS6Q8g130_provenance a np:Provenance . dgn-np:NP484365.RA4_VSli3kAx1b1cPALmw84JL1OiJHzfJThMyeYiS6Q8g130_publicationInfo a np:PublicationInfo . } dgn-np:NP484365.RA4_VSli3kAx1b1cPALmw84JL1OiJHzfJThMyeYiS6Q8g130_assertion { miriam-gene:4842 a ncit:C16612 . lld:C0151814 a ncit:C7057 . dgn-gda:DGN5218c5f404cd7cd7de0fc225830a74c6 sio:SIO_000628 miriam-gene:4842, lld:C0151814; a sio:SIO_001121 . } dgn-np:NP484365.RA4_VSli3kAx1b1cPALmw84JL1OiJHzfJThMyeYiS6Q8g130_provenance { dgn-np:NP484365.RA4_VSli3kAx1b1cPALmw84JL1OiJHzfJThMyeYiS6Q8g130_assertion dcterms:description "[We observed that (1) pretreatment of rabbits 24 hours earlier with CCPA (100 microgram/kg IV bolus) or IB-MECA (100 or 300 microgram/kg) resulted in an approximately 35% to 40% reduction in the size of the infarct induced by 30 minutes of coronary artery occlusion and 72 hours of reperfusion compared with vehicle-treated rabbits, whereas pretreatment with the selective A(2A)AR agonist CGS 21680 (100 microgram/kg) had no effect; (2) the delayed cardioprotective effect of CCPA, but not that of IB-MECA, was completely blocked by coadministration of the highly selective A(1)AR antagonist N-0861; (3) inhibition of nitric oxide synthase (NOS) with N(omega)-nitro-L-arginine during the 30-minute occlusion abrogated the infarct-sparing action of CCPA but not that of IB-MECA; and (4) inhibition of ATP-sensitive potassium (K(ATP)) channels with sodium 5-hydroxydecanoate during the 30-minute occlusion blocked the cardioprotective effects of both CCPA and IB-MECA.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:11249876; prov:wasDerivedFrom dgn-void:befree-20140225; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-20140225 pav:importedOn "2014-02-25"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP484365.RA4_VSli3kAx1b1cPALmw84JL1OiJHzfJThMyeYiS6Q8g130_publicationInfo { this: dcterms:created "2014-10-02T12:36:49+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetrdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v2.1.0.0" . dgn-void:disgenetrdf pav:version "v2.1.0" . }